Welcome to our dedicated page for Skye Bioscience SEC filings (Ticker: SKYE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Skye Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Skye Bioscience's regulatory disclosures and financial reporting.
Skye Bioscience, Inc. (SKYE) entered into a Securities Purchase Agreement with Redmile Biopharma Investments III, L.P. establishing an equity line of credit (the “ELOC”) for up to $22,000,000 of common and non-voting common shares. The ELOC size is reduced by equity proceeds from the PIPE above $103,000,000 and is eliminated if funded PIPE proceeds reach $125,000,000.
Skye must, after commencement, direct monthly purchases of up to $2,000,000 of ELOC shares for three years from the PIPE closing, at a price per share based on the lesser of the PIPE Price and Market Price, but not below a 10% discount to the PIPE Price. Skye will also issue Redmile a warrant sized at $5,000,000 divided by the PIPE Price, exercisable from January 1, 2027 to January 1, 2030, with a floor exercise price of 90% of the PIPE Price. Issuances are constrained by a 19.99% Nasdaq exchange cap and a 9.99% beneficial ownership limit, with excess issuances structured as non-voting common stock. Skye agreed to register resales of the ELOC and conversion shares within 10 business days of the PIPE closing.
Skye Bioscience, Inc. (SKYE) reported insider-related sales of common stock by funds associated with director and ten percent owner Andrew J. Schwab. Over August 18–20, 2026, entities including 5AM Ventures II, L.P., 5AM Co-Investors II, L.P., and 5AM Ventures VII, L.P. sold shares at weighted-average prices ranging from $0.33 to $0.41 per share. All holdings are reported as indirect; Schwab is a managing member of the general partners of these funds and disclaims beneficial ownership except to the extent of his pecuniary interest.
Skye Bioscience, Inc. (SKYE) reported that affiliated 5AM investment funds sold shares of its Common Stock. Over August 18–20, 2026, 5AM Ventures II, L.P., 5AM Co-Investors II, L.P. and 5AM Ventures VII, L.P. sold a combined 375,840 shares in open-market or private transactions at weighted-average prices within $0.33–$0.41 per share.
The shares are held by the 5AM funds, whose general partners and managing members, including John Diekman, Kush Parmar, Andrew J. Schwab and Scott M. Rocklage, may be deemed to share voting and investment power but disclaim beneficial ownership beyond their pecuniary interests.
Skye Bioscience, Inc. (SKYE) filed an amendment to update the effective timing of a previously approved reverse stock split. The company states that the related Certificate will become effective at 12:01 a.m. New York time on August 24, 2026, with its common stock beginning to trade on Nasdaq on a split-adjusted basis at that day’s market open. The common stock will continue to trade under the ticker “SKYE”, and the new CUSIP for the post–reverse split shares will be 83086J309. Skye also reiterates that it plans to file a proxy statement with the SEC in connection with its proposed acquisition of Redx Pharma Limited and provides standard cautionary language regarding forward-looking statements and the risks that could affect completion and integration of the transaction and Nasdaq listing compliance.
Skye Bioscience, Inc. (SKYE) is the subject of this Schedule 13D/A, in which 5AM-affiliated funds and individuals update their beneficial ownership and describe a planned strategic combination with Redx Pharma Limited. Skye agreed to acquire all Redx shares via a UK Scheme of Arrangement, exchanging them for Skye common or new non-voting common stock based on an agreed exchange ratio.
On a pro forma fully diluted basis using the treasury stock method, Redx pre-transaction equityholders are expected to own 46.17% of the combined company, Skye pre-transaction equityholders 5.38%, and investors in the concurrent and Redx Series A financings together 48.45%. A concurrent financing of up to $72.9 million in Skye stock is expected to close immediately after the transaction, with 5AM Ventures VII, L.P. committing up to $10 million, and Redx arranging a separate $36.0 million Series A round.
Existing Skye shareholders as of just before closing are expected to receive contingent value rights tied to 90% of net proceeds from specified legacy-asset deals. Skye’s board approved a 1-for-8 reverse stock split effective around August 24, 2026. The 5AM group reports combined beneficial ownership figures including Andrew J. Schwab at 11,273,407 shares (30.2%) based on 35,421,413 Skye shares outstanding as of August 11, 2026, and discloses open-market sales on August 18, 2026 at a weighted average price of $0.38 per share.
Skye Bioscience, Inc. (SKYE) reports that Nasdaq has notified the company it is not in compliance with Nasdaq Capital Market Listing Rule 5550(b)(1) because stockholders’ equity was ($497,307) as of June 30, 2026, below the required $2,500,000. The notice does not immediately affect trading and SKYE shares continue on the Nasdaq Capital Market. Skye has 45 days, until October 2, 2026, to submit a plan to regain compliance, after which Nasdaq may grant up to 180 days from the notice date, to February 14, 2027, to demonstrate compliance. Skye is evaluating alternatives and also continues to pursue its proposed acquisition of Redx Pharma Limited, which will be submitted to Skye stockholders via a proxy statement.
Skye Bioscience, Inc. reported a sharp contraction in its balance sheet as it winds down its legacy obesity program and pursues a merger with Redx Pharma. Total assets fell to $11.0 million at June 30, 2026 from $28.3 million at year-end 2025, driven by lower short-term investments and asset impairments. The company recorded a six-month net loss of $23.3 million, narrower than the prior year, as research and development expenses declined 45% after terminating the CBeyond nimacimab trial and pausing related R&D.
Liquidity remains strained with a working capital deficit of $572,215, cash and short-term investments of $10.1 million, and a disclosed substantial doubt about its ability to continue as a going concern absent completion of the Redx transaction or new financing. Skye increased its estimate for a legal contingency to $5.4 million related to a former-employee proceeding. To address capital needs, Skye agreed to acquire Redx via a Scheme of Arrangement, supported by a $67.9–$72.9 million concurrent equity financing, a separate $36.0 million Redx Series A round, an equity line of credit of up to $22.0 million, and a $5.0 million warrant. The board also approved a planned 1-for-8 reverse stock split as it works to maintain Nasdaq listing compliance.
Skye Bioscience entered a definitive agreement to acquire Redx Pharma via a UK scheme of arrangement and combine as Fibrx Therapeutics, a fibrosis-focused biotech expected to trade on Nasdaq and be led by the current Redx management team and board.
Based on the agreed Exchange Ratio and assumed financings, pre-transaction Redx holders are expected to own about 46.17% of the combined company, pre-transaction Skye holders about 5.38%, and investors in the concurrent and Series A financings about 48.45%, on a fully diluted basis, subject to net cash and other adjustments. Aggregate gross proceeds of roughly $125 million from a $67.9 million concurrent private financing, a $36.0 million Redx Series A round and related structures, plus an equity line facility of up to $22.0 million, are expected to fund operations into 2029, including a planned Phase 2 trial of lead asset RXC008 with topline data expected in the second half of 2028.
Skye will implement a 1‑for‑8 reverse stock split, reducing outstanding common shares from 35,421,413 to about 4,427,676 to support compliance with Nasdaq’s minimum bid price rule. Pre-transaction Skye stockholders will receive one contingent value right per share, giving them 90% of net cash proceeds, if any, from future monetization of nimacimab and related intellectual property over a defined period. Certain Redx holders will receive similar CVRs tied to Redx legacy assets.
DHILLON PUNIT reported acquisition or exercise transactions in this Form 4 filing.
Skye Bioscience CEO Punit Dhillon received a grant of 1,090,000 restricted stock units tied to common stock on August 7, 2026. Each RSU represents one share and will vest on August 31, 2027, subject to continued employment or certain termination conditions under his Executive Employment Agreement. Following this award, he reports 1,419,823 shares held directly plus 9,343 shares held indirectly through a trust.
Skye Bioscience, Inc. is moving its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market after falling out of compliance with the Global Market’s $10,000,000 minimum stockholders’ equity requirement. The company reported stockholders’ equity of $9,011,804 as of March 31, 2026.
Nasdaq approved the transfer effective with the open of business on June 23, 2026, and the trading symbol “SKYE” will remain unchanged. Separately, Skye previously received notice that its shares traded below the $1.00 minimum bid price for 30 consecutive business days, triggering a 180-day compliance period ending September 14, 2026. The company plans to monitor its share price and consider options to regain compliance but notes there is no assurance it will succeed.